Sofosbuvir based regimen of antiviral therapy for patients with chronic hepatitis C virus infection 1) Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2 2) Real world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus related decompensated cirrhosis

慢性C型肝炎ウイルス感染患者に対するソフォスブビルをベースとした抗ウイルス治療について　1）C型肝炎ウイルスジェノタイプ２型感染患者におけるソフォスブビル+リバビリン治療の有効性の予測因子および肝硬度の変化について　2）C型肝炎ウイルス関連非代償性肝硬変患者に対するソフォスブビル+ベルパタスビル治療の実臨床における有効性について

Oya Kazuki

eng

1) (c) 2018 Wiley Periodicals, Inc.

2) (c) 2020 The Japan Society of Hepatology

1) Ohya, K, Akuta, N, Suzuki, F, et al. Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2. J Med Virol. 2018; 90: 919-925

2) Ohya, K., Imamura, M., Teraoka, Y., Morio, K., Fujino, H., Nakahara, T., Ono, A., Murakami, E., Kawaoka, T., Miki, D., Tsuge, M., Hiramatsu, A., Aikata, H., Hayes, C. N., Mori, N., Takaki, S., Tsuji, K., Aisaka, Y., Ishitobi, T., Katamura, Y., Kodama, H., Nabeshima, Y., Masaki, K., Honda, Y., Moriya, T., Kohno, H., Kohno, H., and Chayama, K. (2020) Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis. Hepatol Res, 50: 1234-1243

[DOI] https://doi.org/10.1002/jmv.25023

[DOI] https://doi.org/10.1111/hepr.13555

広島大学